For US Healthcare Professionals Only
INDICATION AND USAGE
VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
- Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.
Adverse Reactions
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. For additional information about VEVYE, please see the Full Prescribing Information.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Potential for Eye Injury and Contamination – Patients should not touch the bottle tip to the eye or other surfaces.
- Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If worn, lenses should be removed prior to administration and may be reinserted 15 minutes following the administration of VEVYE.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Potential for Eye Injury and Contamination – Patients should not touch the bottle tip to the eye or other surfaces.
INDICATION AND USAGE
VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
- Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.
Adverse Reactions
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. For additional information about VEVYE, please see the Full Prescribing Information.
INDICATION AND USAGE
VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
- Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.
Adverse Reactions
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.
Can we use Cookies?
By clicking “Accept Cookies” below, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.